Please login to the form below

Not currently logged in
Email:
Password:

Bayer's prostate cancer drug fast-tracked

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA)

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin (radium-223 chloride), has been fast-tracked for approval by the US Food and Drug Administration (FDA).

The drug, which is licensed from its developers Algeta ASA, is intended for the treatment of castration-resistant prostate cancer in patients with bone metastases.

The FDA's fast track process is designed to accelerate the review of treatments for serious diseases that fill an unmet need. During the process, increased and more frequent communication is encouraged by the FDA, with the extra level of correspondence intended to lead to earlier drug approvals and patient access to treatments.

Dr Kemal Malik, head of global development at Bayer explained there is a "significant unmet need" for patients in advanced stages of the disease.

He said: "We are excited that Alpharadin has achieved this important milestone and recognise this fast track designation as an important step in the overall development of Alpharadin, particularly for those patients in need of treatment."

Bayer holds the global rights to develop and commercialise Alpharadin. However, in the US, Algeta retains an option for co-promotion and profit-sharing.

23rd August 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Bedrock Group

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics